Skip to main content
Figure 2 | BMC Medical Genetics

Figure 2

From: Pharmacogenetic analysis of the effects of polymorphisms in APOE, IDE and IL1B on a ketone body based therapeutic on cognition in mild to moderate Alzheimer's disease; a randomized, double-blind, placebo-controlled study

Figure 2

Change from Baseline in ADAS-Cog scores among responder genotypes over time. Red markers represent mean change from Baseline among subjects administered AC-1202. Blue markers represent mean change from Baseline among subjects administered Placebo. Error bars represent standard error of the mean. A Solid lines and solid markers represent subjects who are APOE4(-). Dotted lines and solid markers represent mean scores of subjects who are heterozygous for the IDE SNP rs2251101. Dashed lines and open markers represent mean scores of subjects who were E4(-) and heterozygous for the IDE SNP rs2251101. B Solid lines and solid markers represent subjects who are APOE4(-). Dotted lines and solid markers represent mean scores of subjects who are homozygous for the IL1B SNP rs1143627 T allele. Dashed lines and open markers represent mean scores of subjects who were E4(-) and homozygous for the IL1B SNP rs1143627 T allele. Asterisks represent significant difference between AC-1202 and Placebo means (p-value < 0.05).

Back to article page

BMC Medical Genetics

ISSN: 1471-2350

Contact us